Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
6
GOVX Quote, Financials, Valuation and Earnings
Last price:
$1.31
Seasonality move
:
2.94%
Day range:
$1.30 - $1.41
52-week range:
$1.26 - $34.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.27x
P/B ratio:
0.44x
Volume:
89.1K
Avg. volume:
66.5K
1-year change:
-95.49%
Market cap:
$2.1M
Revenue:
$4M
EPS (TTM):
-$1.89
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $270.83 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$55.3M | -$0.87 | 69.18% | -7.84% | $137.27 |
|
SIGA
SIGA Technologies, Inc.
|
-- | -- | -- | -- | -- |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
$1.33 | $270.83 | $2.1M | -- | $0.00 | 0% | 1.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$86.29 | $137.27 | $5.8B | -- | $0.00 | 0% | 28.95x |
|
SIGA
SIGA Technologies, Inc.
|
$5.24 | -- | $381.2M | 16.41x | $0.60 | 0% | 4.03x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.795 | -- | 2.75x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
63.61% | 0.518 | 3.38% | 3.92x |
|
SIGA
SIGA Technologies, Inc.
|
0.4% | 2.342 | 0.34% | 8.79x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$52.5M | -$47.1M | -61.67% | -310.34% | -82.2% | -$26.3M |
|
SIGA
SIGA Technologies, Inc.
|
$804.5K | -$9.5M | 11.1% | 11.15% | -250.38% | -$16.9M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
GeoVax Labs, Inc. vs. Competitors
-
Which has Higher Returns GOVX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of 96.33%. GeoVax Labs, Inc.'s return on equity of -433.69% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About GOVX or ACAD?
GeoVax Labs, Inc. has a consensus price target of $270.83, signalling upside risk potential of 20263.41%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that GeoVax Labs, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe GeoVax Labs, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.3 1 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is GOVX or ACAD More Risky?
GeoVax Labs, Inc. has a beta of 3.805, which suggesting that the stock is 280.533% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock GOVX or ACAD?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or ACAD?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. GeoVax Labs, Inc.'s net income of -$6.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 1.27x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.1.27x -- -- -$6.3M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns GOVX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of 16.99%. GeoVax Labs, Inc.'s return on equity of -433.69% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About GOVX or ALNY?
GeoVax Labs, Inc. has a consensus price target of $270.83, signalling upside risk potential of 20263.41%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that GeoVax Labs, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.3 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is GOVX or ALNY More Risky?
GeoVax Labs, Inc. has a beta of 3.805, which suggesting that the stock is 280.533% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock GOVX or ALNY?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or ALNY?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. GeoVax Labs, Inc.'s net income of -$6.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 1.27x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.1.27x -- -- -$6.3M ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns GOVX or RYTM?
Rhythm Pharmaceuticals, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of -82.97%. GeoVax Labs, Inc.'s return on equity of -433.69% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M -
What do Analysts Say About GOVX or RYTM?
GeoVax Labs, Inc. has a consensus price target of $270.83, signalling upside risk potential of 20263.41%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $137.27 which suggests that it could grow by 59.08%. Given that GeoVax Labs, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.3 1 0 RYTMRhythm Pharmaceuticals, Inc.11 1 0 -
Is GOVX or RYTM More Risky?
GeoVax Labs, Inc. has a beta of 3.805, which suggesting that the stock is 280.533% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.142, suggesting its more volatile than the S&P 500 by 114.237%.
-
Which is a Better Dividend Stock GOVX or RYTM?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or RYTM?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $57.3M. GeoVax Labs, Inc.'s net income of -$6.3M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 1.27x versus 28.95x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.1.27x -- -- -$6.3M RYTMRhythm Pharmaceuticals, Inc.28.95x -- $57.3M -$47.5M
-
Which has Higher Returns GOVX or SIGA?
SIGA Technologies, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of -143.11%. GeoVax Labs, Inc.'s return on equity of -433.69% beat SIGA Technologies, Inc.'s return on equity of 11.15%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M SIGASIGA Technologies, Inc.21.2% -$0.08 $199.6M -
What do Analysts Say About GOVX or SIGA?
GeoVax Labs, Inc. has a consensus price target of $270.83, signalling upside risk potential of 20263.41%. On the other hand SIGA Technologies, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that GeoVax Labs, Inc. has higher upside potential than SIGA Technologies, Inc., analysts believe GeoVax Labs, Inc. is more attractive than SIGA Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.3 1 0 SIGASIGA Technologies, Inc.0 0 0 -
Is GOVX or SIGA More Risky?
GeoVax Labs, Inc. has a beta of 3.805, which suggesting that the stock is 280.533% more volatile than S&P 500. In comparison SIGA Technologies, Inc. has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.923%.
-
Which is a Better Dividend Stock GOVX or SIGA?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. SIGA Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or SIGA?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than SIGA Technologies, Inc. quarterly revenues of $3.8M. GeoVax Labs, Inc.'s net income of -$6.3M is lower than SIGA Technologies, Inc.'s net income of -$5.4M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while SIGA Technologies, Inc.'s PE ratio is 16.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 1.27x versus 4.03x for SIGA Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.1.27x -- -- -$6.3M SIGASIGA Technologies, Inc.4.03x 16.41x $3.8M -$5.4M
-
Which has Higher Returns GOVX or SVRA?
Savara, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of --. GeoVax Labs, Inc.'s return on equity of -433.69% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About GOVX or SVRA?
GeoVax Labs, Inc. has a consensus price target of $270.83, signalling upside risk potential of 20263.41%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that GeoVax Labs, Inc. has higher upside potential than Savara, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.3 1 0 SVRASavara, Inc.6 0 0 -
Is GOVX or SVRA More Risky?
GeoVax Labs, Inc. has a beta of 3.805, which suggesting that the stock is 280.533% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock GOVX or SVRA?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or SVRA?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. GeoVax Labs, Inc.'s net income of -$6.3M is higher than Savara, Inc.'s net income of -$32.2M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 1.27x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.1.27x -- -- -$6.3M SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
